Sjogren’s syndrome:

Fox, Robert I.; Michelśon, Paul E.; Casiano, Carlos A.; Hayashi, Joichiro; Stern, Michael E.

doi:10.1016/s0738-081x(00)00135-8

Cited by 101 publications

(117 citation statements)

References 121 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…In the 9 patients with secondary SS, 18 of the 62 salivary proteins analyzed (29%) were identifiable in a significantly lower percentage of secondary SS patients than in the controls, 2 (IB-1 and statherin) showed significantly lower levels than in the controls, and 3 (IB-6, P-B Des [1][2][3][4] , and ␤-defensin 2) were identifiable in a significantly higher percentage of secondary SS patients than in the controls.…”

Section: Frequencies and Levels Of Salivary Gland Proteins In Primarymentioning

confidence: 90%

“…Saliva specimens were also collected from a subset of 6 of the primary SS patients at 30 minutes, 60 minutes, and 24 hours after a single oral dose of 5 mg of pilocarpine. All patients were diagnosed according to the revised international classification criteria for SS (3).…”

Section: Patients and Controlsmentioning

confidence: 99%

“…Among cholinergic agonists, studies in rats have shown that pilocarpine is the most effective for protein secretion (1) and has mild ␤-adrenergic stimulatory properties; however, few data in humans have been reported. Pilocarpine has been shown to improve symptoms of oral dryness and to increase salivary output in patients with primary Sjögren's syndrome (SS) (2), a chronic autoimmune disorder of the exocrine glands with associated lymphocytic infiltrates and consequent dryness of the mouth and eyes (3).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatment

Peluso¹,

Santis²,

Inzitari³

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To investigate the effect of pilocarpine on the salivary peptide and protein profile in patients with primary Sjögren's syndrome (SS) and to study the differences between patients with primary SS, patients with SS associated with other rheumatic diseases, and healthy control subjects.Methods. Saliva specimens were obtained from 9 primary SS patients, 9 secondary SS patients, and 10 healthy controls. Samples were analyzed for levels of 62 different salivary proteins using high-performance liquid chromatography coupled with mass spectrometry using a spectrometer equipped with an electrospray ionization source. In 6 of the primary SS patients, saliva was collected at 30 minutes, 60 minutes, and 24 hours after taking 5 mg of pilocarpine.Results. Before pilocarpine, ϳ60% of salivary proteins in samples from primary SS patients were not identifiable or showed lower levels than those in healthy controls. After 30-60 minutes following pilocarpine treatment, approximately one-third of the less represented proteins was found in a similar percentage of primary SS patients and controls. Almost all of the proteins that were detectable at lower levels in primary SS patients compared with controls reached levels similar to those in controls at 30-60 minutes after pilocarpine. The parotid gland proteins had the best response to pilocarpine. Primary SS patients were characterized by higher ␣-defensin 1 levels and by the presence of ␤-defensin 2. Secondary SS patients showed an intermediate protein profile between that of the primary SS patients and the controls. Conclusion. Pilocarpine partially restored the levels and numbers of identifiable proteins in saliva from patients with primary SS. Higher levels of ␣-defensin 1 and the presence of ␤-defensin 2 in the saliva of patients with primary SS could be markers of oral inflammation in this patient group.Saliva is a complex fluid composed of a variety of electrolytes, metabolites, nucleotides, polynucleotides, and proteins. This fluid plays an important role in the maintenance of oral health. The rate of salivary protein secretion is controlled mainly by noradrenaline, which is released from the sympathetic terminals and acts through the ␤-adrenergic receptors. The rate of fluid and electrolyte secretion is controlled by acetylcholine, which is released from the parasympathetic terminals and acts through the muscarinic cholinergic receptors.A large number of systemic agents have been proposed as secretagogues, but only a few have shown consistent salivary secretion-enhancing properties in well-designed trials. Among cholinergic agonists, studies in rats have shown that pilocarpine is the most effective for protein secretion (1) and has mild ␤-adrenergic stimulatory properties; however, few data in humans have been reported. Pilocarpine has been shown to improve symptoms of oral dryness and to increase salivary output in patients with primary Sjögren's syndrome (SS) (2), a chronic autoimmune disorder of the exocrine glands with associated lymphocytic infiltrates and con...

show abstract

Section: Frequencies and Levels Of Salivary Gland Proteins In Primarymentioning

confidence: 90%

Section: Patients and Controlsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatment

Peluso¹,

Santis²,

Inzitari³

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…In comparison with patients with SS-HCV without lymphoma, those with lymphoma had a higher frequency of parotid enlargement and vasculitis. In primary SS, parotid enlargement is considered a highly suggestive clinical sign of lymphoma (30,31), while vasculitic features are closely associated with cryoglobulinemia (32) and lymphoma (31,33), with cryoglobulins being predictive factors for lymphoma development (34). Our results suggest a close association between cryoglobulinemic syndrome and lymphoma in patients with SS-HCV, either in its asymptomatic (circulating cryoglobulins) or symptomatic (cryoglobulinemic vasculitis) form.…”

Section: Discussionmentioning

confidence: 67%

Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection

Ramos-Casals

Civita

Vita

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

“…Sjögren's syndrome, a chronic inflammatory autoimmune exocrinopathy, that is characterized by dry eyes and dry mouth clinically and lymphocytic infiltration of lacrimal and salivary glands pathologically 1 . Lung involvement in Sjögren's syndrome usually consists of lymphocytic infiltration similar to that seen in salivary glands and results in tracheobronchial disease or interstitial lung disease 2,3 .…”

Section: Introductionmentioning

confidence: 99%

A Case of Lung Involvement Showing Multiple Lung Cysts in Primary Sjögren's Syndrome

et al. 2008

View full text Add to dashboard Cite

Sjogren’s syndrome:

Cited by 101 publications

References 121 publications

Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatment

Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatment

Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection

A Case of Lung Involvement Showing Multiple Lung Cysts in Primary Sjögren's Syndrome

Contact Info

Product

Resources

About